Opening verdict
Citi Pharma Limited’s year ended 30 June 2026 was a mixed result: the manufacturing engine improved, but the benefit did not reach the bottom line. On the consolidated basis, revenue rose 7.0% to PKR 14.08 billion, gross profit increased 22.6% to PKR 2.47 billion and operating profit advanced 21.0% to PKR 1.94 billion. Yet profit after tax fell 11.4% to PKR 790.3 million and earnings per share declined to PKR 3.46 from PKR 3.90.
The gap between operating progress and net earnings is the central message. Higher finance cost, sharply higher other expenses, lower other income and a larger tax charge absorbed the gross-margin improvement. A factory fire was also material: the annual report describes destroyed inventory of PKR 332.38 million, insurance coverage of PKR 160 million and a net charge of PKR 172.38 million. That is a genuine one-off, but it does not explain every pressure below operating profit.
The year also ended weakly. Reconstructing the June quarter from the audited full-year and nine-month series gives consolidated revenue of PKR 3.29 billion, but a pre-tax loss of PKR 7.5 million and an after-tax loss of PKR 92.7 million. That deterioration matters more than the full-year growth rate alone suggests. The result is therefore best read as stronger core production economics accompanied by weaker financial conversion and a poor final quarter.
Results at a glance
The official PSX result presents both standalone and consolidated numbers. The standalone company reported FY2026 sales of PKR 14.00 billion, gross profit of PKR 2.45 billion, operating profit of PKR 1.93 billion, profit before tax of PKR 1.33 billion and profit after tax of PKR 782.6 million. Consolidated revenue was PKR 14.08 billion and consolidated profit after tax was PKR 790.3 million. Because the group difference is modest but real, this analysis uses consolidated figures for group earnings and cites standalone figures only where the company’s published financial highlights provide the clearest long-run comparison.
On the standalone basis, sales grew 6.5%, gross profit grew 21.4% and operating profit grew 20.0%. Gross margin expanded to 17.49% from 15.34%, while operating margin improved to 13.75% from 12.20%. Profit before tax nevertheless slipped 1.7% and profit after tax fell 12.3%. Net margin compressed to 5.59% from 6.78%, and standalone EPS fell to PKR 3.43 from PKR 3.90.
On the consolidated basis, gross margin improved to 17.57% from 15.34%, an increase of about 2.23 percentage points. Operating margin rose to 13.79% from 12.20%. In contrast, the consolidated net margin fell to 5.62% from 6.78%. Those three margins make the result easy to understand: the business earned more on production and operations, but gave back that progress below operating profit.
No final cash dividend was announced with the FY2026 result. That differs from the prior year, when the company’s historical highlights record cash dividend per share of PKR 3.50. Retaining cash may be understandable given the balance-sheet pressures discussed below, but the filing does not provide a decision-useful allocation bridge that would justify attributing the payout decision to one specific cause.
AlphaGen model scores
The following are AlphaGen model outputs, not figures reported by Citi Pharma: Alpha QoQ Score 8.44; TTM Performance Score 32.44; 3Y Business Perf Score 78.41; Sector Leadership Score 29.87. The contrast is informative: the long-run business score is much stronger than the recent-quarter and sector-relative readings, consistent with a business that has expanded over several years but finished FY2026 poorly.
What improved
Manufacturing economics strengthened
The strongest part of the result was the gross-profit bridge. Consolidated revenue increased by roughly PKR 922 million, while gross profit rose by about PKR 455 million. The annual report indicates lower raw-material consumption of approximately PKR 9.39 billion versus PKR 10.35 billion in the preceding year. That reduction alongside higher sales explains the broad arithmetic of the margin expansion, although the filing does not disclose a complete split among volume, pricing, product mix, procurement and foreign-exchange effects.
Operating profit also grew almost in line with gross profit, implying that the stronger gross contribution was not fully consumed by normal operating overhead. On a standalone basis, operating profit increased by about PKR 321 million. This is important because it shows the improvement was present before financing, exceptional losses and tax, rather than being created by below-the-line income.
Exports added another growth channel
The annual report records export revenue of about PKR 475.7 million, up roughly 29%. Exports remain only about 3.4% of standalone sales, so they are not yet the main earnings driver. Still, the growth broadens the revenue base and provides a useful monitor for whether Citi Pharma can turn its manufacturing platform into a more meaningful foreign-currency stream. The disclosed data do not support a country, product or margin decomposition, so no claim is made that exports were more profitable than domestic sales.
The multi-year top line remains substantially larger
Standalone sales increased from PKR 5.80 billion in FY2021 to PKR 14.00 billion in FY2026, equivalent to compound growth of roughly 19% a year. Gross margin also rose from about 13.5% in FY2021 to 17.5% in FY2026. That longer history supports the view that the company has built scale and improved production economics. It does not, however, remove the volatility visible in net earnings or guarantee that the FY2026 margin is sustainable.
What weakened / needs attention
Below-operating-profit costs overwhelmed the improvement
Consolidated finance cost rose 17.9% to PKR 388.8 million from PKR 329.7 million. Other income fell 53.6% to PKR 91.9 million from PKR 198.3 million. Other expenses increased to PKR 299.0 million from PKR 118.3 million, with the net fire loss explaining PKR 172.38 million of the FY2026 charge. These movements took consolidated profit before tax down slightly to PKR 1.34 billion despite the PKR 336 million increase in operating profit.
Tax then rose to PKR 554.2 million from PKR 462.5 million, an increase of nearly 20%, even though profit before tax declined. The effective tax burden therefore rose materially. The accessible disclosures establish the arithmetic but do not provide enough detail here to separate recurring tax-rate effects, prior-year adjustments and other components with confidence. The prudent conclusion is that tax was a major earnings headwind, not that one unverified tax mechanism caused it.
The June quarter was loss-making
The reconstructed consolidated June quarter is the clearest near-term warning. Revenue increased about 7.7% year on year to PKR 3.29 billion, but gross profit fell to PKR 472.9 million from PKR 561.0 million. Gross margin dropped to about 14.4% from 18.4%. Operating profit fell to PKR 286.4 million from PKR 429.0 million, profit before tax moved from PKR 326.0 million to a PKR 7.5 million loss, and profit after tax moved from PKR 214.0 million to a PKR 92.7 million loss.
The final-quarter numbers are calculated as audited FY2026 less the reported nine months to March 2026. They are therefore comparable discrete-quarter figures, but the company did not publish a complete narrative bridge for the quarter. The data show where earnings deteriorated; they do not establish how much came from price, volume, product mix or timing. Any stronger operational explanation would be speculation.
Liquidity indicators softened
Consolidated cash fell to PKR 208.8 million from PKR 604.0 million. Trade receivables rose 12.7% to PKR 3.47 billion, even as inventory declined 5.5% to PKR 3.71 billion. Total debt increased to PKR 3.10 billion from PKR 2.94 billion, while estimated net debt rose to about PKR 2.89 billion from PKR 2.34 billion. The current ratio eased to approximately 1.25 times from 1.30 times.
This combination—less cash, higher receivables and higher net debt—deserves attention because it can increase financing dependence even when reported operating profit grows. On the positive side, payables and current liabilities declined, and inventory did not build. Still, without a complete FY2026 cash-flow statement in the accessible evidence set, it would be unsafe to claim either strong or weak full-year cash conversion. The analysis therefore stops at balance-sheet movements.
Asset productivity declined
Standalone total assets were broadly stable at PKR 18.12 billion, but the company’s financial highlights show sales-to-total-assets falling to 0.77 times from 0.88 times and sales-to-fixed-assets falling to 1.51 times from 2.06 times. Fixed assets increased to PKR 9.21 billion from PKR 8.69 billion. The business is carrying a larger productive asset base, but FY2026 sales did not yet generate the same turnover per rupee of assets. Future volume growth and utilization will determine whether this is temporary investment drag or a more persistent efficiency issue.
What to monitor next
First, watch gross margin and the June-quarter reversal. The full-year margin improved substantially, but the reconstructed final-quarter margin dropped below the prior-year quarter. The next result needs to show whether lower raw-material consumption and the FY2026 gross-margin gain were durable or whether the year-end weakness carried into FY2027.
Second, track recovery from the fire and the recurrence of other expenses. The PKR 172.38 million net fire loss is separately identifiable and should not be treated as a normal annual cost. Investors should nevertheless distinguish the accounting one-off from any operational disruption, replacement expenditure or insurance timing that may affect later periods.
Third, monitor finance cost, cash and receivables together. A lower policy-rate environment could eventually help borrowing costs, but company-specific benefit depends on debt repricing, average borrowings and working-capital needs. Citi Pharma’s own figures—not a macro assumption—must demonstrate that conversion. Receivables growth should slow relative to sales, cash should stabilize and net debt should stop rising before the financing pressure can be considered resolved.
Fourth, monitor tax normalization. FY2026’s larger tax charge was one of the main reasons profit after tax declined more sharply than profit before tax. A clearer tax reconciliation in subsequent financial statements would help determine how much of the burden is recurring.
Fifth, watch exports and capacity utilization. Export growth was encouraging but came from a small base. The filing does not provide enough verified detail to separate domestic and export margins or quantify utilization by major line. Higher export contribution and better asset turnover would be stronger evidence that recent investment is translating into durable earnings.
Evidence limitations and conclusion
This assessment is a pass with disclosed limitations. The exact company, period, reporting bases and core earnings are verified through the official PSX result, the company’s investor materials and the FY2026 annual report. The full-year cash-flow statement was not available in a reliably extractable form through the evidence routes used here, and quarterly cash-flow data were unavailable in the model history. The article therefore makes no FY2026 cash-conversion claim. It also avoids unsupported volume, pricing and product-mix causality because the filing does not disclose a complete split.
The defensible conclusion is balanced. Citi Pharma delivered real improvement in sales, gross margin and operating profit, and the fire-related loss makes the reported net decline look worse than a normalized reading of core operations. But lower other income, higher finance cost, a heavier tax charge, weaker liquidity indicators and a loss-making final quarter mean the year cannot be called clean. FY2027 needs to convert the stronger manufacturing economics into steadier quarterly profit and cash generation.
Primary sources
Pakistan Stock Exchange — Citi Pharma FY2026 financial result (PDF)
Pakistan Stock Exchange — Citi Pharma FY2026 annual report (PDF)
Citi Pharma — FY2026 annual report (company-hosted PDF)